All in the Genes
By Marcy Darnovsky and Hank Greely,
Democracy
| 08. 31. 2008
Henry Greely inaccurately characterizes my organization, the Center for Genetics and Society, as "drawn to arguments against [inheritable human genetic enhancement] by the lure of naturalness" ["The Genetics of Fear," Issue #9].
I am not sure how Greely reached this conclusion. We explicitly ground our opposition in our commitments to social justice and equality. Procedures that produce (or claim to produce) genetically superior children for those with access to expensive technologies would all too likely exacerbate inequalities and lead to new forms of discrimination.
Greely seems enthusiastic about inheritable genetic modification, but he also recognizes that significant improvements are a long way off. He therefore dismisses proposals, such as the one offered by Jamie Metzl, for international agreements to prohibit socially undesirable human biotechnologies ["Brave New World War," Issue #8]. He disparages efforts at international regulation as "neither progressive nor wise," without mentioning that similar regulations are already in effect, and working well, in over four dozen countries. The United States should join this growing international consensus.
Greely warns ominously that regulating biotechnology "would almost certainly...
Related Articles
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...
By Lauran Neergaard, AP News | 11.03.2025
WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting pig kidneys into people might really save lives.
United Therapeutics, a producer of gene-edited pig kidneys, announced Monday that the study’s initial transplant was performed successfully...